机构：华泰证券 研究员：李健 汽车生态方面，保费同比增长高增34%至14.8 亿元，COR 同比改善3.0pcts至91.2%。2024 年底公司获批 上海、浙江两地的交强险经营资质，1H25完成两地交强险独立经营落地，同时2025 年中开始在上海独 立经营商业车险，带动车险保费快速提升。考虑到车险业务质量提升，我们预计2025 年车险COR 为 92.9%。消费金融生态方面，1H25 实现保费增长24%，与1H24基数较低有关；COR 同比下降5.1pcts 至 94.0%，体现公司审慎经营策略下底层资产质量的改善。预计该业务COR 表现平稳，2025 年为94%。数 字生活生态方面，1H25 总保费下降16%，但是宠物险等创新业务保费同比增长40.0%；COR 维持99.9% 的微盈利水平。预计数字生活的COR 在2025年维持99.9%。 银行扭亏为盈，科技亏损收窄 众安银行实现扭亏，1H25 盈利0.49 亿港元。截至1H25，客户存款为211亿港元（同比+8.8%），净息差 同比提升至2.38%（1H24 2.28%）。众安银行覆盖银行、证券、加密货币交易等业务，并成为首家为稳 定币沙盒发行人提供专 ...

Investment Rating - The report assigns a "Buy" rating to the company, with a target price raised to HKD 23.00, indicating a potential upside of 22.5% from the current closing price of HKD 18.77 [1][7][11]. Core Insights - The company's 1H25 earnings exceeded expectations, with a net profit of RMB 668 million, surpassing the full-year forecast for 2024. This growth is attributed to underwriting profits and the turnaround of its banking operations [2][8]. - Premium income grew by 9.3% year-on-year, primarily driven by the health ecosystem, consumer finance, and automotive sectors, although the digital life ecosystem saw a decline of 16% [8]. - The combined ratio improved year-on-year, with underwriting profits increasing by 109%, mainly from the health ecosystem and consumer finance [8]. - Investment income remained stable, with total investment income growing by 3% year-on-year, and the annualized total/net investment return rates at 3.3%/2.1% [8]. Financial Overview - Revenue projections for the company show a steady increase from RMB 27,535 million in 2023 to RMB 33,504 million in 2025E, with a year-on-year growth rate of 5.5% [6][9]. - Net profit is expected to rise significantly, from RMB 603 million in 2024 to RMB 1,205 million in 2025E, reflecting a growth rate of 99.7% [6][10]. - The report highlights a decrease in the combined ratio from 97.3% to 96.0% for 2025E, indicating improved underwriting efficiency [10][16]. Key Assumptions and Forecasts - The report outlines key assumptions for various segments, with health insurance expected to grow by 33.3% in 2025E, while the digital life segment is projected to decline by 18.7% [9][16]. - The underwriting profit for 2025E is forecasted at RMB 1,334 million, a 34.7% increase from the previous year [10][16]. - The adjusted net profit for 2025E is projected to be RMB 1,205 million, with an EPS of RMB 0.82, reflecting a significant upward revision from previous estimates [10][15].

2 0 25年上半年，众安自营渠道实现总保费36.97亿元，占总保费比例提升至2 2 . 2%，同 比增长达1 6.9%，其中续保保费为人民币1 0 . 3 3亿元，单均保费为人民币5 2 5元，客户续 保率为89. 7%，付费用户人均保单数增至1 . 7张。通过数据驱动的精细化运营，在用户生 命 周 期 价值 挖 掘和 私 域 流 量 转化方 面持续 取 得 突破 ， 为 业 务 高 质 量 发 展 奠 定 了 坚 实 基 础。 8月20日，众安在线发布2025年中期业绩报告。2 0 2 5年上半年，众安实现归母净利润 6 . 68 亿 ， 同 比 增 长 1103.5%； 总 保 费 1 6 6 . 6 1 亿 元 ， 同 比 增 长 9.3%； 承 保 综 合 成 本 率 9 5 .6%，同比优化2 . 3个百分点；公司整体业绩表现亮眼。 从2025年上半年众安利润构成来看，各板块盈利性持续改善，保险分部仍是众安最为重 要的板块。 （一） 总保费稳健增长，自营渠道占比提升，健康与汽车生态增速超30%，表现亮眼 一 保险分部： 2 0 25年上半年，众安实现总保费166.6亿，同比增长9 . 3%，保费增 ...

Core Viewpoint - The mid-year performance report of ZhongAn Online P&C Insurance Co., Ltd. shows significant growth in both underwriting profit and net profit, indicating a strong recovery and strategic positioning in the insurance market [1][3][4]. Group 1: Financial Performance - The company achieved an underwriting profit of 656 million yuan, a year-on-year increase of 108.9% [5]. - Total premium income reached 16.661 billion yuan, reflecting a growth of 9.3% compared to the previous year [3][5]. - Net profit attributable to shareholders was 668 million yuan, a remarkable increase of 1103.5% year-on-year [4][5]. Group 2: Investment Strategy - The company maintains a focus on high liquidity working assets in a low-interest-rate environment, aiming for stable returns while balancing long-term and short-term opportunities [4]. - Total investment income for the first half of the year was 639 million yuan, up 3.1% from 620 million yuan in the same period last year [3][4]. Group 3: Digital Banking and Technology - The digital banking business, under ZA Bank, turned profitable with a net profit of 49 million HKD and a net income of approximately 457 million HKD, marking an 82.1% year-on-year growth [4]. - The company invested 398 million yuan in research and development, focusing on AI, cloud computing, big data, and blockchain to reshape the insurance value chain [10][12]. Group 4: Business Segments - The health insurance segment reported a total premium of 6.275 billion yuan, a significant increase of 38.3% year-on-year, serving approximately 15.21 million insured users [8]. - The auto insurance segment achieved a total premium of 1.478 billion yuan, growing by 34.2% year-on-year, with notable growth in new energy vehicle insurance, which increased by about 125.4% [9]. Group 5: Market Position and External Investment - Norges Bank increased its stake in ZhongAn Insurance, acquiring 1.3481 million shares, raising its holding to 5.07%, indicating confidence in the company's performance and growth potential [5][6]. - The company is positioned to leverage external investments to enhance governance and attract more foreign capital, boosting market confidence [6].

Core Insights - ZhongAn Online reported a total premium of RMB 16.661 billion for the first half of 2025, marking a year-on-year growth of 9.3% [1] - The company achieved an underwriting profit growth of 108.9% and a net profit attributable to shareholders of RMB 668 million, a significant increase of 1103.5% compared to the same period in 2024 [1] Group 1: AI and Technology Integration - ZhongAn is actively integrating AI, blockchain, cloud computing, and big data into its operations, leading the industry in AI technology adoption [2] - The AI platform "Zhong You Lingxi" has become a core engine for business transformation, with nearly 110 active robots and a total of 450 million calls in the first half of 2025 [2] Group 2: Core Business Performance - The health ecosystem's total premium reached RMB 6.275 billion, a year-on-year increase of 38.3%, providing coverage for approximately 15.21 million insured users [3] - The flagship health insurance product "Zunxiang eSheng" generated approximately RMB 4.25 billion in premiums, while the "Zhongminbao" series saw a staggering growth of 638.8% with total premiums of about RMB 1.03 billion [3] Group 3: Digital Life Ecosystem - The digital life ecosystem generated premiums of RMB 6.209 billion, with innovative business premiums reaching RMB 2.49 billion, accounting for 40.1% of the total [4] - The pet insurance segment achieved a premium of nearly RMB 563 million, growing over 51.3%, and ZhongAn has served over 7.11 million pet owners [4] Group 4: Automotive Ecosystem - The automotive ecosystem reported total premiums of RMB 1.478 billion, a year-on-year increase of 34.2% [5] - The company has independently operated compulsory traffic accident insurance in Shanghai and Zhejiang, and the premium for new energy vehicle insurance grew approximately 125.4% [5] Group 5: ZA Bank Performance - ZA Bank, a subsidiary of ZhongAn International, achieved a net profit of HKD 49 million in the first half of 2025, marking a historic turnaround [7] - The bank's net income reached approximately HKD 457 million, a year-on-year increase of 82.1%, with non-interest income growing by 272.1% [7]

Core Insights - The million medical insurance sector has seen significant innovation and upgrades in 2023, with major players expanding coverage to include outpatient treatments and advanced medications [1][2][3] - The competition in the million medical insurance market is intensifying, with companies striving to enhance their offerings to meet evolving consumer demands [5][9] - Despite a slowdown in growth, the market for million medical insurance is expected to continue expanding, driven by increasing healthcare costs and the need for supplementary insurance [10][17] Company Developments - Ant Group's "Good Insurance" series has upgraded its core products to include coverage for specific diseases treated in advanced hospitals and expanded outpatient medication reimbursements [1] - China Life has launched its first 10-year guaranteed renewal product, "Guoshou Kangyue Zhenxiang," which covers outpatient expenses for specific major diseases [2] - ZhongAn Insurance has upgraded its health insurance series, "Zunxiang Esheng" and "Zhongminbao," to include long-term medication coverage and expanded hospitalization benefits [1][2] Market Trends - The million medical insurance market has evolved from high-end and mid-range medical insurance to more affordable options, with products like "Zunxiang Wuyou" and "Eshengbao" gaining popularity [4][9] - The market has seen a shift towards covering outpatient treatments and advanced therapies, with many products now offering zero deductible options [7][8] - The overall scale of the million medical insurance market has grown from negligible in 2016 to approximately 600 billion yuan by 2023, accounting for about 20% of the medical insurance market [9][13] Competitive Landscape - Major players like Renbao Health, ZhongAn, and Ping An Health dominate the market, with their products collectively accounting for a significant share of the total premium income [14][15] - The competitive environment has led to a focus on improving renewal conditions and expanding coverage, with many products now offering guaranteed renewal periods [5][6] - The introduction of lower-cost alternatives like "Hui Min Bao" has created additional pressure on million medical insurance products, although its impact appears to be diminishing [13][21] Future Outlook - The potential for growth in the million medical insurance sector remains strong, with expectations that it could reach a scale of 1.7 to 2.6 trillion yuan by 2029 [18] - The increasing pressure on basic medical insurance is likely to drive demand for commercial health insurance, positioning million medical insurance as a crucial supplement [17][23] - However, challenges such as low claims payout ratios and the need for better customer satisfaction must be addressed to ensure sustainable growth [22][23]

Core Insights - The first domestically approved stem cell therapy drug, Aimi Maitosai injection, has been prescribed for the first time in China [1] - ZhongAn Insurance, as a strategic partner of Albo Bio, includes the Aimi Maitosai injection in its health insurance products, with a maximum reimbursement rate of 100% for eligible claims [1] Company Summary - ZhongAn Insurance has integrated the Aimi Maitosai injection into its core health insurance product lines, including Zunxiang Esheng and Zhongminbao [1] - The inclusion of this stem cell therapy in the insurance coverage represents a significant development in the health insurance sector in China [1] Industry Summary - The approval and prescription of the Aimi Maitosai injection mark a milestone in the stem cell therapy market in China, potentially opening new avenues for treatment and insurance coverage [1] - The collaboration between ZhongAn Insurance and Albo Bio highlights the growing intersection of biotechnology and health insurance, indicating a trend towards more comprehensive coverage for advanced medical treatments [1]